Federated Hermes, Inc. Cue Biopharma, Inc. Transaction History

Federated Hermes, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.49 - $5.92 $11,722 - $27,871	-4,708 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$4.41 - $12.28 $2,279 - $6,348	-517 Reduced 9.89%	4,708 $23,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $15,095 - $24,811	1,390 Added 36.25%	5,225 $59,000
Q3 2021 Nov 15, 2021	BUY	$10.06 - $15.3 $36,004 - $54,758	3,579 Added 1398.05%	3,835 $56,000
Q2 2021 Aug 16, 2021	SELL	$10.9 - $14.53 $1,907 - $2,542	-175 Reduced 40.6%	256 $3,000
Q4 2020 Feb 12, 2021	SELL	$11.12 - $16.4 $1.07 Million - $1.58 Million	-96,583 Reduced 99.56%	431 $5,000
Q3 2020 Nov 12, 2020	SELL	$15.05 - $23.54 $3.57 Million - $5.59 Million	-237,418 Reduced 70.99%	97,014 $1.46 Million
Q2 2020 Aug 13, 2020	BUY	$12.7 - $30.73 $3.14 Million - $7.6 Million	247,446 Added 284.47%	334,432 $8.2 Million
Q1 2020 May 13, 2020	BUY	$9.85 - $22.27 $748,836 - $1.69 Million	76,024 Added 693.52%	86,986 $1.23 Million
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $77,391 - $191,506	10,962 New	10,962 $174,000

14M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $45.3M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.